Trump administration announces “Great Healthcare Plan” proposal centered on legislative action to secure most-favored-nation drug pricing

President Donald Trump has called on Congress to enact a new “Great Healthcare Plan,” positioning the package as a pathway to lower prescription drug prices by locking in most-favored-nation (MFN) pricing agreements and expanding direct-to-consumer purchasing through TrumpRx. The White House says the framework would also seek to reduce insurance premiums and strengthen price transparency measures, though the announcement provides limited detail on implementation and would require legislative action. 

President Donald Trump has announced what the White House described as a broad healthcare framework designed to reduce healthcare costs, with prescription drug pricing presented as a central pillar. Branded the “Great Healthcare Plan,” the proposal calls on Congress to advance four priorities: lowering drug prices; reducing insurance premiums; strengthening accountability among health insurers; and expanding price transparency. The plan is framed as a continuation of the administration’s wider drug pricing agenda, including the May 2025 executive order directing federal agencies to pursue MFN price targets and support direct-to-consumer purchasing models. 

The plan calls on Congress to codify the administration’s MFN deals, which the White House says are intended to bring US drug prices closer to the lowest prices paid in other developed countries. The White House also states that previously negotiated voluntary agreements with the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) would be “grandfathered in,” allowing existing MFN-related agreements to remain in force without being renegotiated if the policy is enacted. 

In remarks accompanying the announcement, Trump framed the approach as an effort to “lock in” discounts achieved through MFN pricing. In the White House article summarizing the plan, the President said the proposal would “bring down drug prices 80, 90% in some cases,” and urged Congress to “complete the work that we’ve started.”  

The framework also points to expanded consumer access routes. The Great Healthcare Plan webpage states that it would make more “verified safe” pharmaceutical drugs available for over-the-counter purchase, with the administration linking this to increased competition and reduced reliance on physician visits for certain medicines. Trump also referenced TrumpRx.gov as part of the rollout, describing it as a pathway for Americans to access lower-priced medicines.  

Beyond drug pricing, the framework outlines measures tied to the plan’s other stated priorities of reducing insurance premiums, strengthening health insurer accountability, and expanding price transparency. The White House says it would stop directing “extra” taxpayer-funded subsidy payments to insurers and instead send that funding to eligible Americans to help them purchase coverage of their choice, alongside a cost-sharing reduction program for health plans. Trump framed this proposal as a direct benefit for consumers, saying: “The government is going to pay the money directly to you. It goes to you, and then you take the money and buy your own healthcare… the big insurance companies lose and the people of our country win.” 

The Great Healthcare Plan also calls for stronger standards for health insurers “so consumers can make better insurance purchasing decisions.” Proposed measures include requiring insurers to publish rate and coverage comparisons upfront on their websites in plain English, disclose the percentage of revenue paid out in claims versus overhead and profits, and report the percentage of claims denied, as well as average wait times for routine care. 

In addition, the plan proposes expanded price transparency requirements, calling for any provider or insurer that accepts Medicare or Medicaid to prominently post pricing and fees at the point of care.